View Filing Data

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	May 31, 2016	Jul. 05, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	ORAMED PHARMACEUTICALS INC.
Entity Central Index Key	0001176309
Amendment Flag	false
Current Fiscal Year End Date	--08-31
Document Type	10-Q
Document Period End Date	May 31, 2016
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		13,136,658

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	May 31, 2016	Aug. 31, 2015
CURRENT ASSETS:
Cash and cash equivalents	$ 3,302	$ 3,213
Short-term deposits	18,040	11,928
Marketable securities	3,363	2,088
Restricted cash	16	16
Prepaid expenses and other current assets	421	127
Total current assets	25,142	17,372
LONG-TERM ASSETS:
Long-term deposits and investment	10,601	8,022
Marketable securities	535	940
Amounts funded in respect of employee rights upon retirement	10	9
Property and equipment, net	17	11
Total long-term assets	11,163	8,982
Total assets	36,305	26,354
CURRENT LIABILITIES:
Accounts payable and accrued expenses	646	953
Deferred revenues (note 1a1)	650	500
Related parties	42	36
Total current liabilities	1,338	1,489
LONG-TERM LIABILITIES:
Deferred revenues (note 1a1)	3,945
Employee rights upon retirement	13	11
Provision for uncertain tax position	26	26
Total long-term liabilities	3,984	37
COMMITMENTS (note 2)
STOCKHOLDERS' EQUITY:
Common stock, $0.012 par value (30,000,000 authorized shares; 13,130,914 and 11,563,077 shares issued and outstanding as of May 31, 2016 and August 31, 2015, respectively)	157	138
Additional paid-in capital	71,768	59,184
Accumulated other comprehensive income	314	558
Accumulated loss	(41,256)	(35,052)
Total stockholders' equity	30,983	24,828
Total liabilities and stockholders' equity	$ 36,305	$ 26,354

Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	May 31, 2016	Aug. 31, 2015
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.012	$ 0.012
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	13,130,914	11,563,077
Common stock, shares outstanding	13,130,914	11,563,077

Condensed Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	May 31, 2016	May 31, 2015	May 31, 2016	May 31, 2015
Income Statement [Abstract]
REVENUES	$ 163		$ 288
RESEARCH AND DEVELOPMENT EXPENSES, NET	1,718	915	4,926	3,353
GENERAL AND ADMINISTRATIVE EXPENSES	555	719	1,833	1,857
OPERATING LOSS	2,110	1,634	6,471	5,210
FINANCIAL INCOME	(137)	(51)	(330)	(105)
FINANCIAL EXPENSES	23		63	11
NET LOSS FOR THE PERIOD	1,996	1,583	6,204	5,116
UNREALIZED LOSS (GAIN) ON AVAILABLE FOR SALE SECURITIES	(84)	(63)	244	289
TOTAL OTHER COMPREHENSIVE LOSS (INCOME)	(84)	(63)	244	289
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	$ 1,912	$ 1,520	$ 6,448	$ 5,405
LOSS PER COMMON SHARE:
BASIC AND DILUTED LOSS PER COMMON SHARE	$ 0.15	$ 0.15	$ 0.50	$ 0.48
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING BASIC AND DILUTED LOSS PER COMMON STOCK	13,118,611	10,827,898	12,450,497	10,598,692

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 9 months ended May 31, 2016 - USD ($)
$ in Thousands

Total

Common Stock

Additional paid-in capital

Accumulated other comprehensive income

Accumulated loss

BEGINNING BALANCE at Aug. 31, 2015

$ 24,828

$ 138

$ 59,184

$ 558

$ (35,052)

BEGINNING BALANCE, Shares at Aug. 31, 2015

11,563

CHANGES DURING THE NINE-MONTH PERIOD ENDED MAY 31, 2016:

SHARES ISSUED FOR SERVICES

^[1]

SHARES ISSUED FOR SERVICES, Shares

ISSUANCE OF COMMON STOCK, NET

10,594

$ 14

10,580

ISSUANCE OF COMMON STOCK, NET, Shares

1,155

EXERCISE OF WARRANTS AND OPTIONS

1,338

$ 4

1,334

EXERCISE OF WARRANTS AND OPTIONS, Shares

331

STOCK BASED COMPENSATION

590

$ 1

589

STOCK BASED COMPENSATION, Shares

NET LOSS

(6,204)

OTHER COMPREHENSIVE LOSS

(244)

ENDING BALANCE at May. 31, 2016

$ 30,983

$ 157

$ 71,768

$ 314

$ (41,256)

ENDING BALANCE, Shares at May. 31, 2016

13,131

[1]	Represents an amount of less than $1.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	May 31, 2016	May 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (6,204)	$ (5,116)
Adjustments required to reconcile net loss to net cash used in operating activities:
Depreciation	3	4
Exchange differences and interest on deposits	(120)	(35)
Stock-based compensation	590	1,029
Common stock issued for services	81	69
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(294)	339
Accounts payable, accrued expenses and related parties	(301)	(208)
Deferred revenue	4,095
Liability for employee rights upon retirement	2	1
Total net cash used in operating activities	(2,148)	(3,917)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(9)	(2)
Purchase of short-term and long-term deposits	(17,385)	(11,525)
Proceeds from sale of short-term deposits	8,870	12,701
Purchase of held to maturity securities	(1,775)
Proceeds from maturity of held to maturity securities	600
Funds in respect of employee rights upon retirement	(1)	(1)
Total net cash (used in) derived from investing activities	(9,700)	1,173
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and vested restricted stock units net of issuance expenses	10,594	4,833
Proceeds from exercise of warrants and options	1,338	8
Total net cash provided by financing activities	11,932	4,841
EFFECT OF EXCHANGE RATE CHANGES ON CASH AND CASH EQUIVALENTS	5	(12)
INCREASE IN CASH AND CASH EQUIVALENTS	89	2,085
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD	3,213	1,762
CASH AND CASH EQUIVALENTS AT END OF PERIOD	$ 3,302	$ 3,847

Significant Accounting Policies

9 Months Ended

May 31, 2016

Significant Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 1 - SIGNIFICANT ACCOUNTING POLICIES:

General:

Incorporation and operations

Oramed Pharmaceuticals Inc. (collectively with its subsidiary, the “Company”, unless the context indicates otherwise) was incorporated on April 12, 2002, under the laws of the State of Nevada. From incorporation until March 3, 2006, the Company was an exploration stage company engaged in the acquisition and exploration of mineral properties. On February 17, 2006, the Company entered into an agreement with Hadasit Medical Services and Development Ltd (“Hadasit”) to acquire the provisional patent related to orally ingestible insulin capsule to be used for the treatment of individuals with diabetes.

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

On November 30, 2015, the Company entered into a Technology License Agreement with Hefei Tianhui Incubation of Technologies Co. Ltd. (“HTIT”) and on December 21, 2015 the parties entered into an Amended and Restated Technology License Agreement (the “License Agreement”). According to the License Agreement, the Company granted HTIT an exclusive commercialization license in the territory of the Peoples Republic of China, Macau and Hong Kong (the “Territory”), related to the Company’s oral insulin capsule, ORMD-0801. Pursuant to the License Agreement, HTIT will conduct, at its own expense, certain pre-commercialization and regulatory activities with respect to the Subsidiary’s technology and ORMD-0801 capsule, and will pay to the Subsidiary (i) royalties of 10% on net sales of the related commercialized products to be sold by HTIT in the Territory (“Royalties”), and (ii) an aggregate of $37,500, of which $3,000 is payable immediately, $8,000 will be paid subject to the Company entering into certain agreements with certain third parties, and $26,500 will be payable upon achievement of certain milestones and conditions. In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the expiration of the Company's patents covering the technology in the Territory (the “Patents”), the Royalties rate may be reduced, under certain circumstances, to 5%.

The Royalties term will commence upon the commercialization of the product and will end upon the later of the expiration of the Patents or fifteen years after the first commercialization of the product in the Territory.

The initial payment of $3,000 was received in January 2016.

Among others, the Company's involvement through the product submission date will include consultancy for the pre-commercialization activities in the Territory, as well as provide advice to HTIT on an ongoing basis.

The closing of the License Agreement was conditioned upon the approval of the Israel Innovation Authority (previously the Office of the Chief Scientist) of the Israeli Ministry of Economy & Industry ("Israel Innovation Authority"), which was received on December 21, 2015.

In July 2015, according to the letter of intent signed between the parties or their affiliates, HTIT's affiliate paid the Subsidiary a non-refundable amount of $500 as a no-shop fee. The no-shop fee was deferred and the related revenue is recognized over the estimated term of the License Agreement (see below).

In addition, on November 30, 2015, the Company entered into a Stock Purchase Agreement (“SPA”) with HTIT. According to the SPA, the Company issued 1,155,367 shares of common stock to HTIT. The transaction closed on December 28, 2015.

The License Agreement and the SPA were considered a single arrangement with multiple deliverables. The Company allocated the total consideration of $49,500 between the License Agreement and the SPA according to their fair value, as follows: $10,617 was allocated to the issuance of shares (less of issuance expenses of $23), based on the quoted price of the Company's share on the closing date of the SPA at December 28, 2015, and $38,883 to the License Agreement. Given the Company's continuing involvement through the expected product submission (June 2023), amounts received relating to the License Agreement are recognized over the period from which the Company is entitled to the respective payment, and the expected product submission date.

As a result, out of a total of $4,883, which was allocated to the License Agreement, revenues in the amount of $288 and $163 were recognized in the nine and three month periods ended May 31, 2016, respectively, and $4,595 was deferred as of May 31, 2016.

Development and liquidity risks

The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Continued operation of the Company is contingent upon obtaining sufficient funding until it becomes profitable.

Successful completion of the Company’s development programs and its transition to normal operations is dependent upon obtaining necessary regulatory approvals from the U.S. Food and Drug Administration prior to selling its products within the United States, and foreign regulatory approvals must be obtained to sell its products internationally. There can be no assurance that the Company will receive regulatory approval of any of its product candidates, and a substantial amount of time may pass before the Company achieves a level of revenues adequate to support its operations, if at all. The Company also expects to incur substantial expenditures in connection with the regulatory approval process for each of its product candidates during their respective developmental periods. Obtaining marketing approval will be directly dependent on the Company’s ability to implement the necessary regulatory steps required to obtain marketing approval in the United States and in other countries. The Company cannot predict the outcome of these activities.

Based on its current cash resources and commitments, and cash received in private and public offerings in the nine month period ended May 31, 2016 and in the year ended August 31, 2015, as well as the investment made by HTIT, the Company believes it will be able to maintain its current planned development activities and the corresponding level of expenditures for at least the next 12 months beyond the date that the financial statements are issued, although no assurance can be given that it will not need additional funds prior to such time. If there are unexpected increases in general and administrative expenses or research and development expenses, the Company may need to seek additional financing during the next 12 months.

Loss per common share

Basic and diluted net loss per common share are computed by dividing the net loss for the period by the weighted average number of shares of common stock outstanding. Outstanding stock options, warrants and restricted stock units have been excluded from the calculation of the diluted loss per share because all such securities are anti-dilutive for all periods presented. The total number of common stock options, warrants and restricted stock units excluded from the calculation of diluted net loss was 2,740,656 and 2,036,965 for the nine month periods ended May 31, 2016 and 2015, respectively, and 2,584,518 and 2,226,165 for the three month periods ended May 31, 2016 and 2015, respectively, because the effect would be anti-dilutive.

Revenue recognition

Revenue is recognized when delivery has occurred, evidence of an arrangement exists, title and risks and rewards for the products are transferred to the customer, collection is reasonably assured and product returns can be reliably estimated.

Given the Company's continuing involvement through the expected product submission (June 2023), revenue from the License Agreement is recognized over the periods from which the Company is entitled to the respective payments (including milestones), and through the expected product submission date.

Newly issued and recently adopted Accounting Pronouncements

In May 2014, the Financial Accounting Standards Board (“FASB”) issued guidance on revenue from contracts with customers that will supersede most current revenue recognition guidance, including industry-specific guidance. The underlying principle is that an entity will recognize revenue upon the transfer of goods or services to customers in an amount that the entity expects to be entitled to in exchange for those goods or services. The guidance provides a five-step analysis of transactions to determine when and how revenue is recognized. Other major provisions include capitalization of certain contract costs, consideration of the time value of money in the transaction price, and allowing estimates of variable consideration to be recognized before contingencies are resolved in certain circumstances. The guidance also requires enhanced disclosures regarding the nature, amount, timing and uncertainty of revenue and cash flows arising from an entity’s contracts with customers. The guidance is effective for the interim and annual periods beginning on or after December 15, 2017 (early adoption is permitted for the interim and annual periods beginning on or after December 15, 2016). The Company is currently evaluating the impact of the guidance on its consolidated financial statements.

In January 2016, the FASB issued guidance on recognition and measurement of financial assets and financial liabilities (Accounting Standards Update No. 2016-01) that will supersede most current guidance. Changes to the current United States generally accepted accounting principles (“U.S. GAAP”) model primarily affect the accounting for equity investments, financial liabilities under the fair value option and the presentation and disclosure requirements for financial instruments. In addition, the FASB clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities.

The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities, is largely unchanged. The classification and measurement guidance will be effective in fiscal years beginning after December 15, 2017, including interim periods within those fiscal years (early adoption of the provision to record fair value changes for financial liabilities under the fair value option resulting from instrument-specific credit risk in other comprehensive income is permitted). The Company is currently evaluating the impact of the guidance on its consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, "Leases (Topic 842)" (“ASU 2016-02”), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in ASU 2016-02 are effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its consolidated financial statements.

In March 2016, the FASB issued ASU 2016-09, "Compensation - Stock Compensation (Topic 718)" ("ASU 2016-09") which simplifies certain aspects of the accounting for share-based payments, including accounting for income taxes, classification of awards as either equity or liabilities, classification on the statement of cash flows as well as allowing an entity-wide accounting policy election to either estimate the number of awards that are expected to vest or account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted in any annual or interim period for which financial statements have not yet been issued, and all amendments in the ASU that apply must be adopted in the same period. The Company is currently evaluating the new guidance to determine the impact it may have on its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326)” ("ASU 2016-13"). ASU 2016-13 requires that financial assets measured at amortized cost be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis. The income statement reflects the measurement of credit losses for newly recognized financial assets, as well as the expected credit losses during the period. The measurement of expected credit losses is based upon historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 will become effective for the Company for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. Early adoption is permitted as of the fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company is currently evaluating the impact of the guidance on its consolidated financial statements.

Condensed Consolidated Financial Statements Preparation

The condensed consolidated financial statements included herein have been prepared in accordance with U.S. GAAP and on the same basis as the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended August 31, 2015 (the “2015 Form 10-K”). These condensed consolidated financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the Securities and Exchange Commission. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2015 Form 10-K. The results for interim periods are not necessarily indicative of a full fiscal year’s results.

Commitments

9 Months Ended

May 31, 2016

Commitments [Abstract]

COMMITMENTS

NOTE 2 - COMMITMENTS:

In March 2011, the Subsidiary sold shares of its investee company, Entera Bio Ltd (“Entera”) to D.N.A Biomedical Solutions Ltd (“D.N.A”), retaining a 3% interest as of March 2011, which is accounted for as a cost method investment (amounting to $1). In consideration for the shares sold to D.N.A, the Company received, among other payments, 8,404,667 ordinary shares of D.N.A (see also note 4).

As part of this agreement, the Subsidiary entered into a patent transfer agreement according to which, the Subsidiary assigned to Entera all of its right, title and interest in and to the patent application that it has licensed to Entera since August 2010. Under this agreement, the Subsidiary is entitled to receive from Entera royalties of 3% of Entera’s net revenues (as defined in the agreement) and a license back of that patent application for use in respect of diabetes and influenza. As of May 31, 2016, Entera had not yet realized any revenues and had not paid any royalties to the Subsidiary.

In addition, as part of a consulting agreement with a third party, dated February 15, 2011, the Subsidiary is obliged to pay this third party royalties of 8% of the net royalties received in respect of the patent that was sold to Entera in March 2011.

On April 28, 2013, the Subsidiary entered into a lease agreement for its office facilities in Israel. The lease agreement is for a period of 35 months commencing November 1, 2013.

The annual lease payment will be New Israeli Shekel 89 thousands ($23) from 2014 through 2016, and will be linked to the increase in the Israeli consumer price index (“CPI”) (as of May 31, 2016, the future lease payments until the expiration of the lease agreement will be $8, based on the exchange rate as of May 31, 2016).

As security for its obligation under this lease agreement the Company provided a bank guarantee in an amount equal to three monthly lease payments.

On July 22, 2014, the Subsidiary entered into a Clinical Research Organization Service Agreement (“CRO Service Agreement”) and on February 29, 2016 into an amendment to the CRO Service Agreement with a third party, to retain it as a Clinical Research Organization (“CRO”), for its Phase 2b clinical trial for an oral insulin capsule for type 2 diabetes patients, which began in the second quarter of calendar year 2015 and completed in the second quarter of calendar year 2016. As consideration for its services, the Subsidiary will pay the CRO a total amount of approximately $3,841 during the term of the engagement and based on achievement of certain milestones, $3,473 of which were recognized through May 31, 2016.

On May 11, 2016, the Subsidiary entered into a Master Service Agreement with a vendor to retain its services for a pre-clinical toxicology trial for an oral GLP-1 analog capsule for type 2 diabetes patients. As consideration for its services, the Subsidiary will pay the vendor a total amount of $1,200 during the term of the engagement and based on achievement of certain milestones, of which $240 was recognized through May 31, 2016.

On May 31, 2016, the Company entered into a consulting agreement with a third party advisor for a period of one year, pursuant to which such advisor will provide investor relations services and will be entitled to receive a monthly cash fee and 10,000 shares of the Company’s common stock that will be issued in four equal quarterly installments commencing August 1, 2016.

Grants from the Bio-Jerusalem Fund (“Bio-Jerusalem”).

The Subsidiary is committed to pay royalties to Bio-Jerusalem on proceeds from future sales at a rate of 4% and up to 100% of the amount of the grant received (Israeli CPI linked) at the total amount of $65.

During the nine month period ended May 31, 2016, the Company received no grants from Bio-Jerusalem.

As of May 31, 2016, the Subsidiary had realized revenues from its project in the amount of $154 and incurred a liability to pay royalties of $6.

Grants from the Israel Innovation Authority.

Under the terms of the Company’s funding from the Israel Innovation Authority, royalties of 3.5% are payable on sales of products developed from a project so funded, up to a maximum amount equaling 100%-150% of the grants received (dollar linked) with the addition of interest at an annual rate based on LIBOR.

At the time the grants were received, successful development of the related projects was not assured. In case of failure of a project that was partly financed as above, the Company is not obligated to pay any such royalties.

The total amount that was received through May 31, 2016 was $2,194.

Royalty expenses are included in the statement of comprehensive loss as a component of the research and development expenses and were $5 and $3 during the nine and three month periods ended May 31, 2016, respectively.

As of May 31, 2016, the Subsidiary had realized revenues from its project in the amount of $154 and incurred a liability to pay royalties of $5.

Fair Value

9 Months Ended

May 31, 2016

Fair Value [Abstract]

FAIR VALUE

NOTE 3 - FAIR VALUE:

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

Level 1:

Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2:

Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

Level 3:

Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

As of May 31, 2016, the assets or liabilities measured at fair value are comprised of available for sale equity securities (level 1).

In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible.

As of May 31, 2016, the carrying amount of cash and cash equivalents, short-term deposits and other current assets and accounts payable and accrued expenses approximate their fair values due to the short-term maturities of these instruments.

As of May 31, 2016, the carrying amount of long-term deposits approximates their fair values due to the stated interest rates which approximate market rates.

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Marketable Securities

9 Months Ended

May 31, 2016

Marketable Securities [Abstract]

MARKETABLE SECURITIES

NOTE 4 - MARKETABLE SECURITIES:

The Company's marketable securities include investments in equity securities of D.N.A and in held to maturity bonds.

Composition:


	May 31, 2016		August 31, 2015
Short-term:
D.N.A (see b below)	$	909	$	1,153
Held to maturity bonds (see c below)		2,454		935
	$	3,363	$	2,088
Long-term:
Held to maturity bonds (see c below)	$	535	$	940

D.N.A

The investment in D.N.A is reported at fair value, with unrealized gains and losses, recorded as a separate component of other comprehensive income in equity until realized. Unrealized losses that are considered to be other-than-temporary are charged to statement of operations as an impairment charge and are included in the consolidated statement of operations under impairment of available-for-sale securities.

The D.N.A ordinary shares are traded on the Tel Aviv Stock Exchange and have a quoted price. The fair value of those securities is measured at the quoted prices of the securities on the measurement date.

During the nine month periods ended May 31, 2016 and May 31, 2015, the Company did not sell any of the D.N.A ordinary shares.

As of May 31, 2016, the Company owns approximately 8.7% of D.N.A’s outstanding ordinary shares.

The cost of the securities as of May 31, 2016 and August 31, 2015 is $595.

Held to maturity bonds

The amortized cost and estimated fair value of held-to-maturity securities at May 31, 2016, are as follows:

	May 31, 2016
	Amortized cost		Gross unrealized losses		Estimated fair value
Short-term:
Commercial bonds	$	2,430	$	-	$	2,430
Accrued interest		24		-		24

Long-term		535		2		537
	$	2,989	$	2	$	2,991

As of May 31, 2016, the contractual maturities of debt securities classified as held-to-maturity are as follows: after one year through two years, $535, and the yield to maturity rate is 1.8%.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References + Details

Stockholders' Equity

9 Months Ended

May 31, 2016

Stockholders' Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 5 - STOCKHOLDERS’ EQUITY

On December 28, 2015, the Company completed a private placement of 1,155,367 shares of the Company's common stock to HTIT. See also note 1.

On January 4, 2016, the Company’s President, Chief Executive Officer and director (the “CEO”), in his capacity as a shareholder of the Company, and a leading investor of the Company, terminated a letter agreement dated November 29, 2012, between the parties, which entitled the leading investor to certain stock compensation from the CEO under certain conditions.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74567-122707

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(d))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Stock Based Compensation	9 Months Ended
Stock Based Compensation	May 31, 2016
Stock-Based Compensation [Abstract]
STOCK-BASED COMPENSATION	NOTE 6 - STOCK-BASED COMPENSATION On November 19, 2015, options to purchase an aggregate of 22,000 of the Company’s shares of common stock were granted to two consultants at an exercise price of $7.36 per share (equivalent to the traded market price on the date of grant). 10,000 of the options vested in one installment on December 1, 2015, and the remaining 12,000 options vest in twelve equal quarterly installments, commencing January 1, 2016. All the options will expire on November 19, 2025. The fair value of the remaining 12,000 options as of May 31, 2016 was $79, using the following assumptions: dividend yield of 0%; expected term of 9.48 years; expected volatility of 79.48%; and risk-free interest rate of 1.84%. The fair value of the unvested options is remeasured at each balance sheet reporting date and is recognized over the related service period using the straight-line method.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References + Details

Subsequent Event

9 Months Ended

May 31, 2016

Subsequent Event [Abstract]

SUBSEQUENT EVENT

NOTE 7 - SUBSEQUENT EVENT

On June 13, 2016, the Subsidiary entered into a four-year service agreement with a third party. This agreement is part of the requirements of the License Agreement as described in note 1. According to the service agreement, the third party will provide services to HTIT regarding certain parts of the manufacturing of the product known as ORMD-0801 in the Territory at HTIT's facilities. The Subsidiary is obligated to pay the third party a total amount of up to €2,360 thousand ($2,660), out of which €800 thousand ($902) is a non-refundable fee to be paid within 12 months from the effective date. The remaining fee will be paid over the term of the engagement and will be based on achievement of certain milestones.

Significant Accounting Policies (Policies)

9 Months Ended

May 31, 2016

Significant Accounting Policies [Abstract]

General:

Incorporation and operations

On May 14, 2007, the Company incorporated a wholly-owned subsidiary in Israel, Oramed Ltd. (the “Subsidiary”), which is engaged in research and development.

On March 11, 2011, the Company was reincorporated from the State of Nevada to the State of Delaware.

The initial payment of $3,000 was received in January 2016.

Development and liquidity risks

Loss per common share

b.	Loss per common share

Revenue recognition

c.	Revenue recognition

Newly issued and recently adopted Accounting Pronouncements

d.	Newly issued and recently adopted Accounting Pronouncements

Condensed Consolidated Financial Statements Preparation

e.	Condensed Consolidated Financial Statements Preparation

Marketable Securities (Tables)

9 Months Ended

May 31, 2016

Marketable Securities [Abstract]

Schedule of marketable securities include investments in equity securities


	May 31, 2016		August 31, 2015
Short-term:
D.N.A (see b below)	$	909	$	1,153
Held to maturity bonds (see c below)		2,454		935
	$	3,363	$	2,088
Long-term:
Held to maturity bonds (see c below)	$	535	$	940

Summary of amortized cost and estimated fair value of of held-to-maturity securities

	May 31, 2016
	Amortized cost		Gross unrealized losses		Estimated fair value
Short-term:
Commercial bonds	$	2,430	$	-	$	2,430
Accrued interest		24		-		24

Long-term		535		2		537
	$	2,989	$	2	$	2,991

- Definition

Tabular disclosure of all investments in certain debt and equity securities for which the entity has the positive intent and ability to hold until maturity.

+ References + Details

Significant Accounting Policies (Details) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended
	Dec. 28, 2015	Jan. 31, 2016	Jul. 31, 2015	May 31, 2016	May 31, 2015	May 31, 2016	May 31, 2015
Significant Accounting Policies (Textual)
Securities excluded from the calculation of diluted net loss				2,584,518	2,226,165	2,740,656	2,036,965
Total consideration						$ 49,500
Recognized revenues				$ 163		288
Recognized deferred revenue				$ 4,595		4,595
Total allocated revenues						4,883
Amended and Restated Technology License Agreement [Member]
Significant Accounting Policies (Textual)
Initial payment of amended and restated technology license agreement		$ 3,000
Issuance of shares [Member]
Significant Accounting Policies (Textual)
Total consideration						10,617
Quaoted price on closing date [Member]
Significant Accounting Policies (Textual)
Total consideration						$ 38,883
Hefei Tianhui Incubation of Technologies Co. Ltd [Member]
Significant Accounting Policies (Textual)
Royalties percentage on net sales						10.00%
Aggregate principal payment						$ 37,500
Value held by subsidiary paid in front						3,000
Periodic payment of agreement						8,000
Value held by subsidiary payable upon achievement						$ 26,500
Royalty commitment description						In the event that the Company does not meet certain conditions, the Royalties rate may be reduced to a minimum of 8%. Following the expiration of the Company's patents covering the technology in the Territory (the "Patents"), the Royalties rate may be reduced, under certain circumstances, to 5%.
Nonrefundable subsidiary amount			$ 500
Common stock issued	1,155,367

Commitments (Details) ₪ in Thousands, $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended
Commitments (Details) ₪ in Thousands, $ in Thousands	May 11, 2016 USD ($)	Jul. 22, 2014 USD ($)	Mar. 31, 2011 USD ($) shares	May 31, 2016 USD ($)	May 31, 2015 USD ($)	May 31, 2016 USD ($) shares	May 31, 2015 USD ($)	May 31, 2016 ILS (₪)	Feb. 15, 2011
Commitments (Textual)
Research and development expense				$ 1,718	$ 915	$ 4,926	$ 3,353
Office Building [Member]
Commitments (Textual)
Operating lease term						35 months
Annual lease payments from 2014 through 2016				23		$ 23		₪ 89
Future annual lease payments				$ 8		$ 8
Bio-Jerusalem [Member]
Commitments (Textual)
Royalty percentage				4.00%		4.00%		4.00%
Maximum percentage of royalties on grants received						100.00%
Grants receivable				$ 65		$ 65
Revenue from project						154
Liability to pay royalties				$ 6		$ 6
Israel Innovation Authority [Member]
Commitments (Textual)
Royalty percentage				3.50%		3.50%		3.50%
Grants received						$ 2,194
Revenue from project						154
Liability to pay royalties				$ 5		5
Research and development expense				$ 3		$ 5
Israel Innovation Authority [Member] \| Minimum [Member]
Commitments (Textual)
Maximum percentage of royalties on grants received						100.00%
Israel Innovation Authority [Member] \| Maximum [Member]
Commitments (Textual)
Maximum percentage of royalties on grants received						150.00%
Entera Bio [Member] \| D.N.A. [Member]
Commitments (Textual)
Cost method investments			$ 1
Ownership percentage retained			3.00%
Ordinary shares received \| shares			8,404,667
Royalty percentage			3.00%
Consultant [Member]
Commitments (Textual)
Royalty percentage									8.00%
Advisor [Member]
Commitments (Textual)
Shares issued for investor relations services \| shares						10,000
Clinical Research Organization Service Agreement [Member]
Commitments (Textual)
Commitments for consulting services		$ 3,841
Consulting services		$ 3,473
Master Service Agreement [Member]
Commitments (Textual)
Commitments for consulting services	$ 1,200
Consulting services	$ 240

Marketable Securities (Details) - USD ($) $ in Thousands	May 31, 2016	Aug. 31, 2015
Short-term:
D.N.A (see b below)	$ 909	$ 1,153
Held to maturity bonds (see c below)	2,454	935
Marketable securities	3,363	2,088
Long-term:
Held to maturity bonds (see c below)	$ 535	$ 940

Marketable Securities (Details1) $ in Thousands	May 31, 2016 USD ($)
Net Investment Income [Line Items]
Amortized cost	$ 2,989
Gross unrealized losses	2
Estimated fair value	2,991
Long term [Member]
Net Investment Income [Line Items]
Amortized cost	535
Gross unrealized losses	2
Estimated fair value	537
Accrued interest [Member] \| Short term [Member]
Net Investment Income [Line Items]
Amortized cost	24
Gross unrealized losses
Estimated fair value	24
Commercial bonds [Member] \| Short term [Member]
Net Investment Income [Line Items]
Amortized cost	2,430
Gross unrealized losses
Estimated fair value	$ 2,430

Marketable Securities (Details Textual) - USD ($) $ in Thousands	9 Months Ended
	May 31, 2016	Aug. 31, 2015
Marketable Securities (Textual)
Percentage of ownership interest	8.70%
Cost of securities	$ 595	$ 595
Yield to cost rates	1.80%
Held to maturity bonds	$ 535	$ 940

Stockholders' Equity (Details)	Dec. 28, 2015 shares
Hefei Tianhui Incubation of Technologies Co. Ltd [Member]
Shareholder's Equity (Textual)
Common stock issued	1,155,367

Stock Based Compensation (Details) $ / shares in Units, $ in Thousands			1 Months Ended	9 Months Ended
	Jan. 01, 2016 Installments shares	Dec. 01, 2015 Installments shares	Nov. 19, 2015 $ / shares shares	May 31, 2016 USD ($) shares
Stock-Based Compensation (Textual)
Expected dividend yield				0.00%
Expected volatility				79.48%
Options granted			22,000
Options granted, exercise price \| $ / shares			$ 7.36
Expiration date			Nov. 19, 2025
Fair value of options granted \| $				$ 79
Options vested in period	12,000	10,000		12,000
Number of vesting installments \| Installments	12	1
Risk-free interest rate				1.84%
Expected term				9 years 5 months 23 days

Subsequent Event (Details) - Jun. 13, 2016 - Subsequent Event [Member] - Subsidiaries [Member] € in Thousands, $ in Thousands	USD ($)	EUR (€)	EUR (€)
Subsequent Event (Textual)
Due to third party	$ 2,660		€ 2,360
Non-refundable fee	$ 902	€ 800